# A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)

Study · id `cardio:ct-nct01370603` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01370603](<https://clinicaltrials.gov/study/NCT01370603>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01370603

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 328 participants.

## Technical summary

Registry record NCT01370603. Randomized; double masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-07-10.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 328 participants (enrolled count; ClinicalTrials.gov record NCT01370603, source copy `cardio:ctgov-nct01370603-2022-02-09`, retrieved 2026-10-31)
- Start date: 2011-09 (registry gives no type) (ClinicalTrials.gov record NCT01370603, source copy `cardio:ctgov-nct01370603-2022-02-09`, retrieved 2026-10-31)
- Primary completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01370603, source copy `cardio:ctgov-nct01370603-2022-02-09`, retrieved 2026-10-31)
- Completion: 2012-05 (actual) (ClinicalTrials.gov record NCT01370603, source copy `cardio:ctgov-nct01370603-2022-02-09`, retrieved 2026-10-31)
- Results first posted: 2013-07-10 (ClinicalTrials.gov record NCT01370603, source copy `cardio:ctgov-nct01370603-2022-02-09`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01370603-2022-02-09`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
- Condition: Hypercholesterolemia
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Ezetimibe
- Intervention (Drug): Ezetimibe/atorvastatin
- Intervention (Drug): Placebo to atorvastatin
- Intervention (Drug): Placebo to ezetimibe
- Intervention (Drug): Placebo to ezetimibe/atorvastatin
- Lead sponsor: Organon and Co
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Ezetimibe (`cardio:ezetimibe`)
- Registry lists this organization as the lead sponsor: Organon and Co (`cardio:org-organon-and-co`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model (`cardio:pubmed-25431239`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3799dc0b3cd02a08ac3ad3bd814194dfea5d93242b9fecdd34aeba308f3816d6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
